ABL is pleased to announce its participation to the recently launched TINN2 (Treat Infections in Neonates 2) program. TINN2 is a European research network (Collaborative Project) supported by the European Commission under the Health Cooperation Work Program of the 7th Framework Program.
ABL will participate to this European research network of excellence and provide the centralized IT platform to collect pharmacological and clinical trial data to the researchers for the evaluation of azythromycin for the treatment of infections in preterm and term neonates. The network will work on evaluating various pediatric formulations across Europe in order to apply for a Pediatric-Use Marketing Authorization (PUMA) application and ultimately, to improve neonatal care as a direct benefit to children, their families and health professionals.
See the brochure